The ‘Metabolic Divide’ has been formalised with the commercial rollout of the HOBIT ‘living pharmacy’ and the first commercial Brain-Computer Interfaces. No longer content with leasing us our housing and our software, capital has now moved to lease us our own internal biology. The HOBIT implant, a wireless platform capable of producing therapies internally, effectively gates metabolic health behind a monthly paywall. For the global elite, longevity and cognitive enhancement are becoming premium features; for the rest, health remains a deteriorating public utility.

The approval of Borui Kang’s BCI in China and the move toward high-volume production at Neuralink signal the opening of the ‘neural frontier.’ While these technologies are framed as breakthroughs for stroke survivors and the paralysed, their structural function is the commodification of the human nervous system. We are witnessing the birth of ‘Synthetic Serfdom,’ where the very ability to think and heal is mediated by corporate terms of service. As Eli Lilly and Novo Nordisk move metabolic management to subscription-only models, the body itself is becoming an enclosure. The practice of medicine is being replaced by the management of a market commodity, further alienating the human being from their own physiological agency.